Abstract
Ipilimumab (anti CTLA-4 antibody) aims to activate antitumor immunity. Thistreatment is being evaluated in non-small cell lung cancer.Case report.-We report a case of a stage IV adenocarcinoma patient randomized in 2008 in thephase II trial CA 184-104 evaluating the combination of ipilimumab to chemotherapy with car-boplatin and paclitaxel. After an initial partial response to chemotherapy, the patient achieveda complete response with ipilimumab as maintenance therapy. However, it was complicatedby grade 3 gastro-intestinal toxicity leading to stop the ipilimumab. However, this completeresponse persists after 6 years.Conclusions.-Our case illustrates the contribution of immunotherapy at least in some patients.The mechanisms of action, relationship between efficacy and toxicity and predictors of efficacyremain to be defined.
Translated title of the contribution | Ipilimumab and metastatic lung cancer: Can we change the natural history of the disease? |
---|---|
Original language | French |
Pages (from-to) | 949-952 |
Number of pages | 4 |
Journal | Revue des Maladies Respiratoires |
Volume | 32 |
Issue number | 9 |
DOIs | |
Publication status | Published - 1 Nov 2015 |
Externally published | Yes |